ReCode Therapeutics

We are proud to announce that ReCode’s lead therapeutic candidate, RCT1100, has received U.S. FDA Orphan Drug Designation for the treatment of primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene. PCD is a rare genetic lung disorder that currently has no FDA-approved treatments, so receiving this designation is an important recognition for the PCD patient community. We want to thank the entire ReCode team for their continued persistence in unlocking the potential of precision mRNA and gene correction therapeutics. We also thank the PCD Foundation, all people living with PCD, and their families for providing the feedback and insights that shape our research and power our progress. Learn more about RCT1100 here: https://lnkd.in/gv647SZs

At ReCode Therapeutics, we’re laser-focused on groundbreaking genetic medicine for cystic fibrosis (CF). As we gather at the North American Cystic Fibrosis Conference 2024, we are excited to showcase our advanced SORT LNP platform and discuss RCT2100, an inhaled therapy for cystic fibrosis designed to deliver CFTR mRNA to target cells and promote the production of functional CFTR protein. We’ll see you at Booth 816 - September 26 - 28 in Boston! #NACFC #NACFC24

Ariel Kantor, PhD, our Senior Vice President of Business and Corporate Development, shares our vision for the future of genetic medicine. At ReCode Therapeutics, we are leveraging enhanced delivery technologies, novel payloads, and AI/Machine Learning-based approaches to revolutionize the treatment of genetic diseases. Ariel explains, "The dream would be to have a scenario where we can [...] go from sequence to vial. Our goal is to engineer specific payloads that can be encapsulated and delivered to treat a broad range of conditions. This approach has the potential to transform the landscape of genetic medicine and provide new options for patients with debilitating genetic conditions.” #GeneticMedicine #TeamReCode

As we celebrate National Hispanic American Heritage Month, we reflect on the profound contributions of Hispanic innovators in biotechnology, whose work continues to inspire and drive progress. At ReCode Therapeutics, we are proud to follow in the footsteps of pioneers like Dr. Lydia Villa-Komaroff, whose groundbreaking research in producing insulin from bacteria has transformed diabetes care, and Dr. Carlos Bustamante, whose leadership in genomics and population genetics is shaping the future of personalized medicine. These scientists have laid the foundation for a more inclusive and effective approach to medicine. At ReCode, we are committed to advancing this legacy by developing targeted therapies that address unmet medical needs, ensuring that everyone has the opportunity to benefit from cutting-edge science. #NationalHispanicAmericanHeritageMonth #HispanicHeritageMonth #DiversityInScience

ICYMI: ReCode’s lead therapeutic candidate, RCT1100, has been granted U.S. FDA Orphan Drug Designation for the treatment of primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene. PCD is a rare genetic lung disorder with no FDA-approved treatments, making this designation a significant milestone for the PCD patient community. We extend our gratitude to the entire ReCode team for their unwavering dedication to advancing precision mRNA and gene correction therapeutics. A special thanks to the PCD Foundation, individuals living with PCD, and their families for their invaluable feedback and insights that continue to shape our research and drive our progress. Learn more about RCT1100 here: https://lnkd.in/gv647SZs

We're honored to participate in the Cilia2024 Research Meeting in Dublin from September 10-13. John Matthews, our Chief Medical Officer, will be in attendance. We look forward to sharing our contributions to the Cilia research space. We’ll see you in Ireland!

We're honored to participate in the Morgan Stanley Healthcare Conference in New York City from September 4-6. We extend our gratitude to the organizers for hosting this event. Shehnaaz Suliman, CEO, and Erica Jefferson, SVP, Corporate Affairs, will be in attendance. We look forward to engaging discussions and collaborations that shape the future of biotechnology. See you in New York City!

We're gearing up to attend the RNA Leaders USA Congress from September 4 - 5 in San Diego, CA. This conference is an essential gathering for professionals dedicated to the future of mRNA therapies. We look forward to speaking on our advancements and learning from the wealth of knowledge presented by experts in the field.

ReCode Therapeutics invites dynamic and committed individuals to join our team. At ReCode, we prioritize "Patients first; beyond all else," and emphasize a culture of inclusivity, welcoming varied insights to propel our mission forward. View available positions below: https://lnkd.in/grQ4DK5F #BiotechCareers #PatientCentric #BiotechCulture

Shehnaaz Suliman, CEO, speaks on the initiation of our Phase 1b study for RCT2100: "Receiving clearance from global regulatory authorities to begin our Phase 1b study of RCT2100 is a significant milestone that represents our relentless pursuit of breakthrough treatments for people with cystic fibrosis, particularly the 10% who do not respond to currently approved CFTR modulators." More information: https://lnkd.in/gqgZCEyU #CysticFibrosis #ClinicalTrials #TeamReCode #mRNA